H.C. Wainwright initiated coverage of Precision BioSciences (NASDAQ:DTIL) with a “buy” rating and $21 price target. The stock closed at $13.76 on July 15. Precision is one of the early adopters of a potential paradigm...
H.C. Wainwright raised its price target for Capricor Therapeutics (NASDAQ:CAPR) to $12.40 from $3.50 after the company posted positive results from an interim analysis of the HOPE-2 trial in patients with Duchenne...
Roth Capital Partners initiated coverage of Akero Therapeutics (NASDAQ:AKRO) with a “buy” rating and price target of $34. The stock closed at $19.88 on July 12. “Although Akero’s lead asset, AKR-001 (a FGF21...
Roth Capital Partners resumed coverage of Syros Pharmaceuticals (NASDAQ:SYRS) with a “buy” rating and $17 price target. The stock was quoted at $8.49 in afternoon trading on July 12. Syros was co-founded by ARCH Venture...
Stifel upgraded Rhythm Pharmaceuticals (NASDAQ:RYTM) to “buy” from “hold” but maintained its price target at $34, saying the stock is at an attractive entry point ahead of near-term Phase 3 results. The stock closed at...
Maxim Group reduced price targets for five biotech stocks, citing data troughs, financing conditions and political factors, which may be further compounded by a lack of catalysts and increasing operating expenses...
Janney Montgomery Scott initiated coverage of Abcam plc (LSE:ABC) with a “buy” rating and fair value estimate of £17. The stock closed at £14.72 on July 1.